Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CORT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Sy… NCT03604198 · Cushing Syndrome relacorilant | CORT Corcept Therapeutics | Phase 2 | Active, not recruiting | 125 | Dec 2026 | Registry ↗ |
| Oct 16, 2026 | Evaluating the Pharmacokinetics and Safety of Miricorilant NCT07553663 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-… Miricorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 14 | Sep 22, 2026 | Registry ↗ |
| Sep 30, 2026 | Evaluation of Miricorilant on Liver Fat in Patients With MASLD NCT06947304 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-… Miricorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 9 | Aug 13, 2026 | Registry ↗ |
| Sep 29, 2026 | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metab… NCT06108219 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-… Miricorilant (Cohort A), Placebo (Cohort A) | CORT Corcept Therapeutics | Phase 2 | Completed | 175 | Feb 13, 2026 | Registry ↗ |
| Sep 25, 2026 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcin… NCT07259317 · Adenocarcinoma, Carcinoma, Pancreatic Ductal Relacorilant, Nab-paclitaxel | CORT Corcept Therapeutics | Phase 2 | Recruiting | 80 | Sep 2027 | Registry ↗ |
| Sep 25, 2026 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithel… NCT05257408 · Ovarian Neoplasm, Fallopian Tube Neoplasms Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2 | CORT Corcept Therapeutics | Phase 3 | Active, not recruiting | 381 | Mar 31, 2025 | Registry ↗ |
| Sep 24, 2026 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis NCT05407324 · Amyotrophic Lateral Sclerosis Dazucorilant 300 mg, Dazucorilant 150 mg | CORT Corcept Therapeutics | Phase 2 | Active, not recruiting | 279 | Oct 2026 | Registry ↗ |
| Aug 19, 2026 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies NCT07276373 · Neoplasms Nenocorilant 200 mg, Nenocorilant 300 mg | CORT Corcept Therapeutics | Phase 1/2 | Recruiting | 50 | Sep 2026 | Registry ↗ |
| Jul 16, 2026 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341 · Ovarian Cancer, Fallopian Tube Cancer Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m… | CORT Corcept Therapeutics | Phase 2 | Recruiting | 270 | Aug 2026 | Registry ↗ |
| May 15, 2026 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metast… NCT03437941 · Metastatic Castration-Resistant Prostate Cancer Exicorilant, Enzalutamide | CORT Corcept Therapeutics | Phase 1/2 | Terminated | 39 | Oct 13, 2021 | Registry ↗ |
| Apr 13, 2026 | Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Health… NCT07240116 · Healthy Miricorilant Treatment A, Miricorilant Treatment B | CORT Corcept Therapeutics | Phase 1 | Completed | 18 | Mar 3, 2026 | Registry ↗ |
| Feb 17, 2026 | Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOM… NCT06829537 · Resistant Hypertension, Hypercortisolism | CORT Corcept Therapeutics | — | Completed | 1,143 | Dec 8, 2025 | Registry ↗ |
| Oct 7, 2025 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resis… NCT03776812 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma Relacorilant, Nab-paclitaxel | CORT Corcept Therapeutics | Phase 2 | Completed | 178 | Mar 16, 2021 | Registry ↗ |
| Sep 4, 2025 | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Aden… NCT04308590 · Hypercortisolism Relacorilant, Placebo | CORT Corcept Therapeutics | Phase 3 | Completed | 137 | Sep 19, 2024 | Registry ↗ |
| Jul 16, 2025 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome NCT03697109 · Cushing Syndrome Relacorilant, Placebo | CORT Corcept Therapeutics | Phase 3 | Completed | 152 | Apr 8, 2024 | Registry ↗ |
| Jul 1, 2025 | Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Partici… NCT06495944 · Healthy Adults Dazucorilant, Itraconazole | CORT Corcept Therapeutics | Phase 1 | Completed | 21 | Aug 2, 2024 | Registry ↗ |
| Apr 15, 2025 | Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant NCT06928779 · Hepatic Impairment Dazucorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 19 | Dec 9, 2024 | Registry ↗ |
| Mar 30, 2025 | Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant NCT05553470 · Non-alcoholic Steatohepatitis (NASH) Miricorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 19 | Sep 13, 2024 | Registry ↗ |
| Jan 20, 2025 | Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatmen… NCT05772169 · Hypercortisolism, Diabetes Mellitus, Type 2 Mifepristone 300 MG [Korlym], Placebo for mifepristone | CORT Corcept Therapeutics | Phase 4 | Completed | 1,113 | Nov 19, 2024 | Registry ↗ |
| Sep 19, 2024 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese… NCT03818256 · Antipsychotic-induced Weight Gain (AIWG) Miricorilant, Placebo | CORT Corcept Therapeutics | Phase 2 | Completed | 71 | Jun 17, 2022 | Registry ↗ |
| Aug 19, 2024 | A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in P… NCT05320146 · Nonalcoholic Steatohepatitis (NASH) MRI-PDFF | CORT Corcept Therapeutics | — | Completed | 22 | Jul 18, 2023 | Registry ↗ |
| Aug 19, 2024 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Pres… NCT05117489 · Nonalcoholic Steatohepatitis (NASH) Miricorilant 150 mg, Miricorilant 100 mg | CORT Corcept Therapeutics | Phase 1 | Completed | 70 | Jan 29, 2024 | Registry ↗ |
| Jun 13, 2024 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patien… NCT04524403 · Antipsychotic-induced Weight Gain (AIWG) Miricorlilant, Miricorlilant | CORT Corcept Therapeutics | Phase 2 | Completed | 150 | Jul 29, 2022 | Registry ↗ |
| Feb 23, 2024 | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma… NCT04373265 · Adrenocortical Carcinoma Relacorilant, Pembrolizumab | CORT Corcept Therapeutics | Phase 1 | Completed | 15 | Oct 17, 2023 | Registry ↗ |
| Nov 18, 2023 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Duc… NCT04329949 · Metastatic Pancreatic Ductal Adenocarcinoma Relacorilant, 100 mg and 25 mg, Nab-paclitaxel | CORT Corcept Therapeutics | Phase 3 | Terminated | 43 | Aug 23, 2021 | Registry ↗ |
| Oct 23, 2023 | A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Health… NCT06094790 · Healthy CORT125134 150 mg, CORT125134 250 mg | CORT Corcept Therapeutics | Phase 1 | Completed | 32 | Nov 15, 2017 | Registry ↗ |
| Oct 23, 2023 | A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subje… NCT06094738 · Healthy Relacorilant under fasted conditions, Relacorilant after a… | CORT Corcept Therapeutics | Phase 1 | Completed | 30 | Nov 16, 2020 | Registry ↗ |
| Oct 23, 2023 | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant NCT06094725 · Hepatic Impairment Relacorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 30 | Dec 14, 2020 | Registry ↗ |
| Oct 23, 2023 | A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subj… NCT06094712 · Healthy CORT125134 | CORT Corcept Therapeutics | Phase 1 | Completed | 8 | Apr 27, 2016 | Registry ↗ |
| Jun 1, 2023 | Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome NCT02663609 · Cushing's Syndrome No intervention | CORT Corcept Therapeutics | — | Completed | 24 | Dec 1, 2017 | Registry ↗ |
| Mar 22, 2023 | Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Mirico… NCT05712265 · Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepa… Miricorilant, Fluvoxamine | CORT Corcept Therapeutics | Phase 1 | Completed | 26 | Feb 23, 2023 | Registry ↗ |
| Mar 22, 2023 | Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants NCT05003713 · Healthy CORT125236, Placebo matching CORT125236 | CORT Corcept Therapeutics | Phase 1 | Completed | 82 | Feb 3, 2023 | Registry ↗ |
| Feb 9, 2023 | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran… NCT05347979 · Cushing Syndrome, Neoplasms Dabigatran Etexilate, Relacorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 30 | Jul 19, 2022 | Registry ↗ |
| Dec 6, 2022 | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With… NCT02762981 · Solid Tumors Relacorilant with nab-paclitaxel | CORT Corcept Therapeutics | Phase 1/2 | Completed | 85 | May 12, 2020 | Registry ↗ |
| Aug 31, 2022 | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Pr… NCT03823703 · Nonalcoholic Steatohepatitis (NASH) Miricorilant, Placebo | CORT Corcept Therapeutics | Phase 2 | Terminated | 12 | Apr 5, 2021 | Registry ↗ |
| Feb 9, 2022 | Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants NCT04672512 · Healthy CORT125329 lipid capsule formulation, Placebo | CORT Corcept Therapeutics | Phase 1 | Completed | 115 | Jan 17, 2022 | Registry ↗ |
| Feb 8, 2022 | A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male… NCT00698022 · Healthy Risperidone, Mifepristone | CORT Corcept Therapeutics | Phase 1 | Completed | 76 | Feb 2009 | Registry ↗ |
| Feb 1, 2022 | Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants NCT04249323 · Healthy Adults CORT113176 Lipid Capsule Formulation, Placebo matching CORT… | CORT Corcept Therapeutics | Phase 1 | Completed | 110 | Oct 15, 2020 | Registry ↗ |
| Nov 24, 2021 | Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Health… NCT04990310 · Healthy [14C]-CORT113176 | CORT Corcept Therapeutics | Phase 1 | Completed | 6 | Sep 20, 2021 | Registry ↗ |
| Oct 11, 2021 | Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants NCT04994743 · Healthy Adults CORT113176, Placebo matching CORT113176 | CORT Corcept Therapeutics | Phase 1 | Completed | 16 | Sep 30, 2021 | Registry ↗ |
| Sep 14, 2021 | T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers NCT04795479 · Healthy Relacorilant, Placebo to relacorilant | CORT Corcept Therapeutics | Phase 1 | Completed | 36 | May 17, 2021 | Registry ↗ |
| Dec 17, 2020 | Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Particip… NCT04672499 · Healthy Miricorilant 300 mg tablets, Miricorilant 150 mg tablets | CORT Corcept Therapeutics | Phase 1 | Completed | 36 | Sep 7, 2020 | Registry ↗ |
| Apr 28, 2020 | The Effect of CORT118335 on Olanzapine-Induced Weight Gain NCT03877562 · Antipsychotic-induced Weight Gain Olanzapine, CORT118335 | CORT Corcept Therapeutics | Phase 1 | Completed | 96 | Mar 13, 2020 | Registry ↗ |
| Mar 24, 2020 | Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and I… NCT03512548 · Healthy Relacorilant 350mg, Itraconazole | CORT Corcept Therapeutics | Phase 1 | Completed | 52 | Jul 29, 2019 | Registry ↗ |
| Oct 15, 2019 | Study to Evaluate CORT125134 in Participants With Cushing's Syndrome NCT02804750 · Cushing's Syndrome CORT125134 | CORT Corcept Therapeutics | Phase 2 | Completed | 35 | Sep 2018 | Registry ↗ |
| Aug 9, 2019 | CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) NCT03508635 · Healthy CORT125134, Matching Placebo of CORT125134 | CORT Corcept Therapeutics | Phase 1 | Completed | 130 | Dec 2015 | Registry ↗ |
| Aug 9, 2019 | A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body NCT03067376 · Healthy [14C]-CORT125134 | CORT Corcept Therapeutics | Phase 1 | Completed | 9 | Sep 2016 | Registry ↗ |
| Jul 30, 2019 | Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome NCT03379363 · Hypercortisolism, Cushing Syndrome | CORT Corcept Therapeutics | — | Terminated | 2 | Feb 12, 2018 | Registry ↗ |
| Jun 11, 2019 | Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants NCT03878264 · Healthy CORT118335 Oral, 14C-CORT118335 intravenous | CORT Corcept Therapeutics | Phase 1 | Completed | 12 | Mar 24, 2019 | Registry ↗ |
| May 24, 2019 | First-in-human Study in Healthy Subjects NCT03315338 · Healthy CORT118335, 25 mg, Prednisone Oral Tablet | CORT Corcept Therapeutics | Phase 1 | Completed | 143 | Feb 22, 2019 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances